# US 2021/0332015 A1 · Compounds and their use for the treatment of alpha1-antitrypsin deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332015 A1
- Document ID: US20210332015A1
- Status: Published application
- Kind: A1
- Application number: 17/345,928
- Filed: 2021-06-11
- Published: 2021-10-28
- Earliest claimed: 2018-12-14
- Assignees: Z Factor Limited
- Applicants: Z Factor Limited
- Inventors: Nigel RAMSDEN; David John FOX; James Andrew HUNTINGTON
- Web page: https://patentgrep.com/patent/US20210332015A1

## CPC

- C07D 239/36: as doubly bound oxygen atom or as unsubstituted hydroxy radical
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of α1-antitrypsin deficiency (A1AD or AATD).

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A compound represented by the structure of:
or a pharmaceutically acceptable salt of any one thereof.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the structure is represented by:
or pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 14)

The compound of claim 14, wherein the structure is represented by:
or pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 14)

The compound of claim 14, wherein the structure is represented by:
or pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 14)

A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 14 and a pharmaceutically acceptable excipient.

### Claim 19 (depends on 14, 18)

A method of treating α1-antitrypsin deficiency (AATD) in a subject in need thereof, the method comprising administering to the subject in need thereof a compound or pharmaceutically acceptable salt of claim 14 or a pharmaceutical composition of claim 18.

### Claim 20 (depends on 19)

The method of claim 19, wherein the administering to the subject in need thereof induces Z α1-Antitrypsin (A1AT) secretion in the subject.

### Claim 21 (depends on 19)

The method of claim 19, wherein the administering to the subject in need thereof increases levels of Z α1-Antitrypsin (A1AT) in the subject.

### Claim 22 (depends on 19)

The method of claim 19, wherein the administering to the subject in need thereof is conducted orally.
